BioTech Medics, Inc. Negotiating SHBAN(TM) Non-Alcohol Hand Sanitizer Brazil Distribution Agreement

  BioTech Medics, Inc. (PINKSHEETS: BMCS)
announced today that it is finalizing a wholesaler Distribution Agreement
for BioTech's SHBAN(TM) Antimicrobial Non-Alcohol Hand Sanitizer Products
with a Brazil distributor.  The final agreement is expected to be signed by
Friday, October 16. The initial income and fees to BioTech for 2009 for the
Brazil Distributorship is $500,000 (US) and projected $2,500,000 (US) in
sales for 2010.

SHBAN is manufactured at an FDA registered plant. It is a bio-degradable product superior to most anti-bacterial hand sanitizers because 1) SHBAN is longer lasting; 2) SHBAN does NOT contain alcohol or alcohol gel which has poisoned over 22,000 children; 3) SHBAN is non-toxic when used as directed on humans; 4) SHBAN is non-staining; 5) SHBAN is non-flammable; and 6) SHBAN contains no ammonia, bleach, Benzalkonium Chloride (BOC), nor Triclosan®, nor thymus vulgaris (which is a potent carcinogen for rodents) or fragrance ingredients. Most hand sanitizer products cannot make all of these claims.

SHBAN is protected under US Letters of Patent #5,514,808, #5,574,050, #5,679,711 and #5,585,391 and a patent pending for the US and international patent. SHBAN is a trademark of BioTech Medics, Inc. BioTech is negotiating more foreign distributorships and will be announcing the signing of additional distributorships soon.

SHBAN(TM) in previous in vitro and in vivo testing has been evaluated for its antimicrobial properties against Staph. Aureus, Staph. Epidermidis, EC. Faecalis, E. Coli and Ps. Aeruginosa. Prior clinical studies have been conducted at the University of Texas Medical Branch, Galveston, TX; Microbiology & Biochemical Assay Laboratories - Houston, TX; Pathology Associates, Pasadena, TX; Texas A & M University - College of Veterinary Medicine, College Station, TX; Baylor College of Dentistry, Dallas, TX; Allergan, Irvine, CA; Culleen Eye Institute, Baylor College of Medicine, Houston, TX.

BioTech is completing independent clinical testing of SHBAN(TM) Hand Sanitizer Solution to determine if it reduces (or kills) the H1N1 (Swine) Influenza A virus.

Interested parties desiring a SHBAN Distributorship should contact BioTech immediately.

Safe Harbor: Forward-Looking Statements

This release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). The statements above have not been evaluated by the FDA. SHBAN is not intended to diagnose, treat or cure any disease.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact: Tom Wood Sr. V.P. Sales Phone [phone]